Biomarkers in Cancer

Novel Molecular Markers for Breast Cancer

Submit a Paper

Biomarkers in Cancer 2016:8 25-42


Published on 13 Mar 2016

DOI: 10.4137/BIC.S38394

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Biomarkers in Cancer


The use of molecular biomarkers assures that breast cancer (BC) patients receive optimal treatment. Established biomarkers, such as estrogen receptor, progesterone receptor, HER2, and Ki67, have been playing significant roles in the subcategorization of BC to predict the prognosis and decide the specific therapy to each patient. Antihormonal therapy using 4-hydroxytamoxifen or aromatase inhibitors have been employed in patients whose tumor cells express hormone receptors, while monoclonal antibody to HER2 has been administered to HER2-positive BCs. Although new therapeutic agents have been developed in the past few decades, many patients still die of the disease due to relapse; thus, novel molecular markers that predict therapeutic failure and those that can be targets for specific therapy are expected. We have chosen four of such molecules by reviewing recent publications, which are cyclin E, B-Myb, Twist, and DMP1β. The oncogenicity of these molecules has been demonstrated in vivo and/or in vitro through studies using transgenic mice or siRNAs, and their expressions have been shown to be associated with shortened overall or disease-free survival of BC patients. The former three molecules have been shown to accelerate epithelial–mesenchymal transition that is often associated with cancer stem cell-ness and metastasis; all these four can be novel therapeutic targets as well. Thus, large prospective studies employing immunohistochemistry will be needed to establish the predictive values of these molecules in patients with BC.




BibTex citation   (BIBDESK, LATEX)


What Your Colleagues Say About Biomarkers in Cancer
Biomarkers in Cancer, was again a pleasant experience.  We received helpful suggestions from the reviewers and an efficient, very professional editing processing process afterwards. Excellent team-work!  We hope for the same quantity of reads/citations as for our previous publication in Clinical Medicine Insights: Oncology.
Dr Cornelis F.M. Sier (Leiden University Medical Center, Netherlands)
More Testimonials

Quick Links

New article and journal news notification services